184 related articles for article (PubMed ID: 24355408)
1. Cutaneous manifestations of anti-angiogenic therapy in oncology: Review with focus on VEGF inhibitors.
Ishak RS; Aad SA; Kyei A; Farhat FS
Crit Rev Oncol Hematol; 2014 May; 90(2):152-64. PubMed ID: 24355408
[TBL] [Abstract][Full Text] [Related]
2. Hypertension and proteinuria: a class-effect of antiangiogenic therapies.
Launay-Vacher V; Deray G
Anticancer Drugs; 2009 Jan; 20(1):81-2. PubMed ID: 19343005
[TBL] [Abstract][Full Text] [Related]
3. [Anti-angiogenesis targeting drugs: a review].
Jia K; Li J
Ai Zheng; 2008 Apr; 27(4):442-6. PubMed ID: 18423135
[TBL] [Abstract][Full Text] [Related]
4. Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer.
Bertolini F; Marighetti P; Martin-Padura I; Mancuso P; Hu-Lowe DD; Shaked Y; D'Onofrio A
Drug Discov Today; 2011 Dec; 16(23-24):1052-60. PubMed ID: 21875682
[TBL] [Abstract][Full Text] [Related]
5. [Renal toxicity of anti-VEGF (corrected) targeted therapies].
Vigneau C; Rioux-Leclercq N
Nephrol Ther; 2013 Jun; 9(3):174-9. PubMed ID: 23410950
[TBL] [Abstract][Full Text] [Related]
6. Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway.
Itatani Y; Kawada K; Yamamoto T; Sakai Y
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670046
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor: biology and therapeutic applications.
Ho QT; Kuo CJ
Int J Biochem Cell Biol; 2007; 39(7-8):1349-57. PubMed ID: 17537667
[TBL] [Abstract][Full Text] [Related]
8. Targeting angiogenesis in head and neck cancer.
Seiwert TY; Cohen EE
Semin Oncol; 2008 Jun; 35(3):274-85. PubMed ID: 18544442
[TBL] [Abstract][Full Text] [Related]
9. Targeting VEGF in lung cancer.
Das M; Wakelee H
Expert Opin Ther Targets; 2012 Apr; 16(4):395-406. PubMed ID: 22439677
[TBL] [Abstract][Full Text] [Related]
10. Angiogenesis and hypertension: the dual role of anti-hypertensive and anti-angiogenic therapies.
Ferroni P; Della-Morte D; Palmirotta R; Rundek T; Guadagni F; Roselli M
Curr Vasc Pharmacol; 2012 Jul; 10(4):479-93. PubMed ID: 22272903
[TBL] [Abstract][Full Text] [Related]
11. Novel targets for VEGF-independent anti-angiogenic drugs.
Petrillo M; Scambia G; Ferrandina G
Expert Opin Investig Drugs; 2012 Apr; 21(4):451-72. PubMed ID: 22339615
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.
Tandle A; Libutti SK
Clin Adv Hematol Oncol; 2003 Jan; 1(1):41-8. PubMed ID: 16227959
[TBL] [Abstract][Full Text] [Related]
13. VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic.
Epstein RJ
Cancer Metastasis Rev; 2007 Dec; 26(3-4):443-52. PubMed ID: 17786538
[TBL] [Abstract][Full Text] [Related]
14. Biological mechanisms of bevacizumab-associated adverse events.
Higa GM; Abraham J
Expert Rev Anticancer Ther; 2009 Jul; 9(7):999-1007. PubMed ID: 19589038
[TBL] [Abstract][Full Text] [Related]
15. Anti-angiogenic treatment of gastrointestinal malignancies.
Salmon JS; Lockhart AC; Berlin J
Cancer Invest; 2005; 23(8):712-26. PubMed ID: 16377590
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
Albiges L; Salem M; Rini B; Escudier B
Hematol Oncol Clin North Am; 2011 Aug; 25(4):813-33. PubMed ID: 21763969
[TBL] [Abstract][Full Text] [Related]
17. Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy.
Horsley L; Marti K; Jayson GC
Expert Opin Drug Metab Toxicol; 2012 Mar; 8(3):283-93. PubMed ID: 22283844
[TBL] [Abstract][Full Text] [Related]
18. Anti-angiogenic drug discovery: lessons from the past and thoughts for the future.
Wu JM; Staton CA
Expert Opin Drug Discov; 2012 Aug; 7(8):723-43. PubMed ID: 22716277
[TBL] [Abstract][Full Text] [Related]
19. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway.
Roodhart JM; Langenberg MH; Witteveen E; Voest EE
Curr Clin Pharmacol; 2008 May; 3(2):132-43. PubMed ID: 18690886
[TBL] [Abstract][Full Text] [Related]
20. Investigational VEGF antagonists for psoriasis.
Crawshaw AA; Griffiths CE; Young HS
Expert Opin Investig Drugs; 2012 Jan; 21(1):33-43. PubMed ID: 22088218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
